Opus Genetics (NASDAQ:IRD) and Kura Oncology (NASDAQ:KURA) Head-To-Head Analysis

Opus Genetics (NASDAQ:IRD) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Opus Genetics and Kura Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Kura Oncology	-384.30%	-207.18%	-45.17%

Valuation & Earnings

This table compares Opus Genetics and Kura Oncology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	23.34	-$49.59 million	($1.35)	-2.97
Kura Oncology	$67.48 million	8.96	-$278.67 million	($3.37)	-2.02

Opus Genetics has higher earnings, but lower revenue than Kura Oncology. Opus Genetics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Opus Genetics and Kura Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	16	1	2.89
Kura Oncology	1	1	11	0	2.77

Opus Genetics presently has a consensus target price of $12.71, suggesting a potential upside of 217.06%. Kura Oncology has a consensus target price of $25.35, suggesting a potential upside of 272.84%. Given Kura Oncology’s higher probable upside, analysts clearly believe Kura Oncology is more favorable than Opus Genetics.

Institutional & Insider Ownership

15.0% of Opus Genetics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Opus Genetics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Summary

Opus Genetics beats Kura Oncology on 10 of the 14 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.